...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>British Journal of Cancer >Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients
【24h】

Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients

机译：烟酰胺与烟酰胺的呼吸改善了患者肿瘤的氧气状态

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Nicotinamide and carbogen breathing are both effective radiosensitisers in experimental tumour models and are even more effective in combination. This study was to investigate the feasibility of using the agents in combination in patients and to measure their effect on tumour oxygenation. Twelve patients with advanced malignant disease were treated with 4-6 g of oral nicotinamide (NCT) in tablet formulation. Ten of these 12 patients breathed carbogen (95% oxygen, 5% carbon dioxide) for up to 20 min at presumed peak plasma NCT concentration (Cpeak) and had tumour oxygen partial pressure (pO2) measured using the Eppendorf pO2) histograph. The mean Cpeak values were 82, 115 and 150 micrograms ml-1 for NCT doses of 4, 5 and 6 g respectively and were dose dependent. The time of Cpeak was independent of dose with an overall mean of 2.4 h (range 0.7-4 h). NCT toxicity occurred in 9 out of 12 patients and was mild in all but one; carbogen was well tolerated in all patients. Following NCT only two patients had significant rises (P < 0.05) in tumour median pO2. During carbogen breathing, eight out of ten patients had early highly significant rises in pO2 (P < 0.0001), of which six continued to rise or remained in plateau until completion of gas breathing. Six patients had hypoxic pretreatment values less than 5 mmHg, which were completely abolished in three and reduced in two during carbogen breathing. In conclusion, the combination of NCT and carbogen breathing was generally well tolerated and gave rise to substantial rises in tumour pO2 which were maintained throughout gas breathing. These results should encourage further study of this potentially useful combination of agents as radiosensitisers in the clinic.
机译：烟酰胺和碳源呼吸在实验肿瘤模型中都是有效的放射增敏剂，联合使用时甚至更有效。这项研究旨在探讨在患者中联合使用这些药物的可行性，并评估其对肿瘤氧合的影响。用片剂制剂中的4-6 g口服烟酰胺（NCT）治疗12名晚期恶性疾病患者。在这12名患者中，有10名在假定的血浆NCT峰值浓度（Cpeak）下呼吸了碳源（95％氧气，5％二氧化碳）长达20分钟，并使用直方图测量了肿瘤氧分压（pO2）。 NCT剂量4、5和6 g的平均Cpeak值分别为82、115和150微克ml-1，并且与剂量有关。 Cpeak的时间与剂量无关，总体平均值为2.4 h（范围0.7-4 h）。 12例患者中有9例发生了NCT毒性反应，除1例外，其余所有症状均较轻。所有患者对碳源的耐受性良好。 NCT后仅两名患者的肿瘤中位数pO2显着升高（P <0.05）。在进行碳氢化合物呼吸期间，十分之八的患者早期出现了pO2的高度显着升高（P <0.0001），其中六名患者继续升高或保持在高原，直到完成气体呼吸为止。六例患者的低氧预处理值低于5 mmHg，在进行碳源呼吸时，其三分之二被完全消除，而二分之三被降低。总之，NCT和碳氢化合物呼吸的组合通常被很好地耐受，并导致肿瘤pO2的大量升高，而这种现象在整个气体呼吸过程中都得以维持。这些结果应鼓励进一步研究这种可能有用的试剂组合作为放射增敏剂在临床中的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号